Hyperprolinemia
A metabolic disorder from proline breakdown failure.
Hyperprolinemia is a disorder of amino acid metabolism in which the body cannot properly break down proline. This happens when either of two enzymes—proline oxidase or pyrroline-5-carboxylate dehydrogenase—is deficient, leading to a buildup of proline.
The condition has two main types, each linked to a different gene. Type I results from mutations in the *PRODH* gene, which codes for proline oxidase. This enzyme starts the breakdown of proline by converting it to pyrroline-5-carboxylate. Some *PRODH* mutations cause only a mild reduction in enzyme activity (less than 30%), others a moderate reduction (30%–70%), and still others a severe reduction (over 70%). One mutation actually increases activity. Several of these variants have been repeatedly found in people with schizophrenia, but the risk appears tied to the gene variant itself rather than to high proline levels, since some risky mutations do not cause hyperprolinemia.
Type II is caused by mutations in the *ALDH4A1* gene, which codes for pyrroline-5-carboxylate dehydrogenase. This enzyme breaks down pyrroline-5-carboxylate into glutamate. When it is deficient, both proline and the intermediate pyrroline-5-carboxylate accumulate, leading to more severe symptoms.
Both types are inherited in an autosomal recessive pattern, meaning a person must have two altered copies of the gene to develop the condition. Parents are usually carriers with one altered copy and no symptoms. In about one-third of hyperprolinemia cases, people with one altered *PRODH* gene have moderately elevated proline levels but no health problems. Those with one altered *ALDH4A1* gene have normal proline levels.
The clinical features of hyperprolinemia are not clearly defined. In type I, some people have no symptoms at all, while others may experience kidney disease, uncontrolled seizures, intellectual disability, or schizophrenia. A benign course without neurological issues has also been reported. Type II is rare and can sometimes appear harmless, but it often involves seizures, convulsions, and intellectual disability. Evidence suggests type II may lower the seizure threshold, making individuals more sensitive to influenza-associated encephalopathy. The severity and manifestations depend on the nature and number of genetic hits affecting the gene.
Quick Facts
- Field
- Medical genetics
Facts from the source article.
Lore & Background
Hyperprolinemia arises from mutations in either the PRODH gene, causing type I, or the ALDH4A1 gene, causing type II. The PRODH gene codes for proline oxidase, which begins proline degradation; the ALDH4A1 gene codes for pyrroline-5-carboxylate dehydrogenase, which converts an intermediate to glutamate. A deficiency of either enzyme leads to proline buildup, with type II also accumulating pyrroline-5-carboxylate.
Clinical features are unclear. Type I has been associated with nephropathy, uncontrolled seizures, intellectual disabilities, and schizophrenia, but a benign phenotype without neurological problems has also been reported. Type II may reduce the threshold for convulsions, increasing sensitivity to triggers like influenza-associated encephalopathy. Treatment is primarily supportive and symptom-based, with no standard dietary or supplement regimen proven to prevent seizures in hyperprolinemia.
Reader's Guide
Hyperprolinemia is significant as a model for understanding amino acid metabolism disorders and the genetic basis of neurological symptoms. The condition highlights the complexity of genotype-phenotype relationships: some individuals with PRODH mutations have no symptoms, while others develop seizures or intellectual disability. The association between certain PRODH variants and schizophrenia risk, independent of hyperprolinemia itself, suggests that the gene may influence brain function beyond its metabolic role. The autosomal recessive inheritance pattern and the observation that carriers of one altered PRODH gene can have moderately elevated proline without health problems underscore the variability in expression. Research on rats indicating cognitive dysfunction and the detection of oxidative stress in brain tissue point to potential therapeutic avenues with antioxidants. The condition also illustrates how metabolic intermediates like pyrroline-5-carboxylate can have secondary effects, such as deactivating pyridoxal phosphate and increasing seizure risk in type II. Overall, hyperprolinemia serves as a cautionary example of how a single metabolic defect can produce a wide range of clinical outcomes, from benign to severe neurological impairment.
Did You Know?
- In about one-third of cases, individuals carrying one copy of an altered PRODH gene have moderately elevated proline levels but no health problems.
- Hyperprolinemia type II results in proline levels 10 to 15 times higher than normal, along with high levels of pyrroline-5-carboxylate.
- A 2005 study on rats suggested that hyperprolinemia causes cognitive dysfunction.
More in Disorders causing seizures 1-24
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced